by Clinical Neuropsychologist Online | Wednesday, February 12, 2025 | Dementia
Abstract The characteristic events in neurodegenerative diseases (NDDs) encompass protein misfolding, aggregation, accumulation, and their related cellular dysfunction, synaptic function loss. While distinct proteins are implicated in the pathological processes of...
by Clinical Neuropsychologist Online | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION Blood–brain barrier (BBB) breakdown is essential in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB), whereas the variability in BBB permeability to water and contrast agent is less clear. METHODS We investigated BBB...
by Clinical Neuropsychologist Online | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION We aimed to compare gait between individuals with Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and cognitively unimpaired (CU) individuals and to evaluate the association between gait and regional amyloid beta (Aβ) burden in...
by Clinical Neuropsychologist Online | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION No studies in India have explored subjective cognitive decline (SCD), a hallmark of stage II of preclinical Alzheimer’s disease. This study aims to assess the prevalence and correlates of SCD in a South Indian, urban, elderly population....
by Clinical Neuropsychologist Online | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION Tau pathology impacts neurodegeneration and cognitive decline in Alzheimer’s disease (AD), with the dorsal raphe nucleus (DRN) being among the brain regions showing the earliest tau pathology. As a serotonergic hub, DRN activity is altered...
